F-group (family)
5000.3.1.1 Bcl-2
Ligands and drugs
626
Member domains
406
with ligand contacts (≤ 4 Å)
64.9% of members
361
with DrugDomain annotations
57.7% of members
118
with a DrugBank compound
18.8% of members
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
Chemical profiles are computed for X-groups. 5000.3.1.1 belongs to X-group 5000 Toxins' membrane translocation domains, which binds 10.9 ligand superclasses per 20 proteins, broader than 98% of the 256 X-groups with enough proteins to compare. View its chemical profile →
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB04327 | PEE | Phosphatidylethanolamine | 6 |
| DB17023 | N3C | ABT-737 | 6 |
| DB01694 | TAR | D-tartaric acid | 2 |
| DB02042 | 1PG | 2-(2-{2-[2-(2-Methoxy-Ethoxy)-Ethoxy]-Ethoxy}-Ethoxy)-Ethanol | 2 |
| DB02676 | B3P | 2-[3-(2-Hydroxy-1,1-Dihydroxymethyl-Ethylamino)-Propylamino]-2-Hydroxymethyl-Propane-1,3-Diol | 2 |
| DB02580 | PG6 | Pentaglyme | 1 |
| DB02774 | PDO | 1,3-Propanediol | 1 |
| DB02994 | CAD | Cacodylic acid | 1 |
| DB03309 | NHE | N-cyclohexyltaurine | 1 |
| DB03627 | ADM | Adamantane | 1 |
| DB07108 | 4FC | 4'-FLUORO-1,1'-BIPHENYL-4-CARBOXYLIC ACID | 1 |
| DB12756 | — | — | 1 |
| DB14792 | E4W | AZD-5991 | 1 |
| DB17166 | VF8 | Tapotoclax | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| ZNmetal | ZINC ION | 26 |
| CL | CHLORIDE ION | 17 |
| 19G | 3-[3-(4-chloro-3,5-dimethylphenoxy)propyl]-1-benzothiophene-2-carboxylic acid | 12 |
| 4M6 | 1-[3-(naphthalen-1-yloxy)propyl]-5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinoline-2-carboxylic acid | 12 |
| 4M7 | (1R)-7-[3-(naphthalen-1-yloxy)propyl]-3,4-dihydro-2H-[1,4]thiazepino[2,3,4-hi]indole-6-carboxylic acid 1-oxide | 12 |
| 8SP | O-[(R)-{[(2R)-2,3-bis(octanoyloxy)propyl]oxy}(hydroxy)phosphoryl]-L-serine | 12 |
| CUmetal | COPPER (II) ION | 11 |
| 6AK | 4-{8-chloro-11-[3-(4-chloro-3,5-dimethylphenoxy)propyl]-1-oxo-7-(1,3,5-trimethyl-1H-pyrazol-4-yl)-4,5-dihydro-1H-[1,4]diazepino[1,2-a]indol-2(3H)-yl}-1-methyl-1H-indole-6-carboxylic acid | 10 |
| PG8 | 1,2-DIOCTANOYL-SN-GLYCERO-3-[PHOSPHO-RAC-(1-GLYCEROL) | 8 |
| 19H | 6-chloro-3-[3-(4-chloro-3,5-dimethylphenoxy)propyl]-1H-indole-2-carboxylic acid | 7 |
| 2UU | 4-(4-methylnaphthalen-1-yl)-2-{[(4-phenoxyphenyl)sulfonyl]amino}benzoic acid | 6 |
| K6G | [(2~{R})-2-oxidanyl-3-[oxidanyl-[2-(trimethyl-$l^{4}-azanyl)ethoxy]phosphoryl]oxy-propyl] hexadecanoate | 6 |
| LC6 | 7-(4-{[(4-{[(2R)-4-(dimethylamino)-1-(phenylsulfanyl)butan-2-yl]amino}-3-nitrophenyl)sulfonyl]carbamoyl}-2-methylphenyl)-3-[3-(naphthalen-1-yloxy)propyl]pyrazolo[1,5-a]pyridine-2-carboxylic acid | 6 |
| N3C | 4-{4-[(4'-CHLOROBIPHENYL-2-YL)METHYL]PIPERAZIN-1-YL}-N-{[4-({(1R)-3-(DIMETHYLAMINO)-1-[(PHENYLTHIO)METHYL]PROPYL}AMINO)-3-NITROPHENYL]SULFONYL}BENZAMIDE | 6 |
| PEE | 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine | 6 |
| 43B | 3-NITRO-N-{4-[2-(2-PHENYLETHYL)-1,3-BENZOTHIAZOL-5-YL]BENZOYL}-4-{[2-(PHENYLSULFANYL)ETHYL]AMINO}BENZENESULFONAMIDE | 4 |
| 5X2 | 3-[3-(4-chloranyl-3,5-dimethyl-phenoxy)propyl]-~{N}-(phenylsulfonyl)-1~{H}-indole-2-carboxamide | 4 |
| 5X3 | 5-[[6-chloranyl-3-[3-(4-chloranyl-3,5-dimethyl-phenoxy)propyl]-7-(3,5-dimethyl-1~{H}-pyrazol-4-yl)-1~{H}-indol-2-yl]carbonylsulfamoyl]furan-2-carboxylic acid | 4 |
| 6AL | 3-({6-chloro-3-[3-(4-chloro-3,5-dimethylphenoxy)propyl]-7-(1,3,5-trimethyl-1H-pyrazol-4-yl)-1H-indole-2-carbonyl}amino)benzoic acid | 4 |
| BR | BROMIDE ION | 4 |